TITLE

Effects of Combination Therapy with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber and Oral Vancomycin on Fulminant Pseudomembranous Colitis with Septic Shock

AUTHOR(S)
Yoshihide Kimura; Koichi Sato; Hiroshi Tokuda; Naka Nakamura; Yasuaki Dohi; Etsuro Orito; Masashi Mizokami
PUB. DATE
March 2007
SOURCE
Digestive Diseases & Sciences;Mar2007, Vol. 52 Issue 3, p675
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract??We report 2 cases of fulminant pseudomembranous colitis with septic shock. The first case showed few symptoms, whereas the second case showed recurrence. Both cases rapidly developed shock and blood pressure was uncontrollable except with the use of pressor agents. Direct hemoperfusion using polymyxin B-immobilized fiber, which was previously demonstrated to have excellent therapeutic effects for the treatment of hypotension in septic shock by removing circulating lipopolysaccharide and oral vancomycin dramatically improved both cases? clinical status and decreased their APACHE II scores (from 18 to 8 and from 16 to 9 points, respectively). Therefore, we suggest that direct hemoperfusion using polymyxin B-immobilized fiber improved hypotension-correcting cytokine balance with adsorption of endogenous cannabinoids in serum. Although colectomy is often performed to treat fulminant pseudomembranous colitis with septic shock, direct hemoperfusion can be easily performed with little risk to the patient. These cases strongly indicated that our combination therapy provides an important treatment for fulminant pseudomembranous colitis with septic shock.
ACCESSION #
24079640

 

Related Articles

  • Polymyxin B hemoperfusion in septic shock: just look at the evidence! Antonelli, Massimo; Cutuli, Salvatore; Ronco, Claudio // Intensive Care Medicine;Sep2015, Vol. 41 Issue 9, p1731 

    A letter to the editor is presented in response to the article "Early Use of Polymyxin B Hemoperfusion in Patients With Septic Shock Due to Peritonitis: A Multicenter Randomized Control Trial" by D. M. Payen and colleagues in the 2015 issue.

  • TREATMENT OF ULCERATIVE COLITIS WITH A RESION POLYMYXIN PHTHALYLSULFACETAMIDE PREPARATION. Ehrlich, Robert // American Journal of Gastroenterology;Feb1960, Vol. 33 Issue 2, p235 

    Twenty-four patients with ulcerative colitis were treated with a combined preparation of Resion, polymyxin and phthalylsulfacetamide. Each patient was observed by sigmoidoscopy prior, during, and after therapy. Complete regression of the ulcerative process resulted in 71 per cent while an...

  • Early recovery in hemodynamics after direct hemoperfusion with polymyxin B-immobilized fibers may predict mortality rate in patients with septic shock. Kobayashi, Atsuko; Iwasaki, Yasushi; Kimura, Yuichi; Kawagoe, Yoshiaki; Ujike, Yoshihito // Journal of Anesthesia;2010, Vol. 24 Issue 5, p709 

    Purpose: This retrospective and observational study attempted to determine whether the rapid improvement in hemodynamic parameters and the subsequent discontinuation or decrease of catecholamine infusion shortly after direct hemoperfusion with polymyxin B-immobilized fibers (PMX) may be strong...

  • Direct hemoperfusion with polymyxin B immobilized fiber for abdominal sepsis in Europe. SATO, KOICHI; MAEKAWA, HIROSHI; SAKURADA, MUTSUMI; ORITA, HAJIME; KOMATSU, YOSHIHIRO // Surgery Today;Jun2011, Vol. 41 Issue 6, p754 

    Since direct hemoperfusion with polymyxin B immobilized fiber (PMX-DHP) received its product certification for use in Europe in 1998, several prospective randomized controlled trials (RCTs) have been conducted in European countries. The first RCT, performed in six European academic medical...

  • Vancomycin use in 2 Ontario tertiary care hospitals: a survey. Kwan, Terry; Lin, Frank // Clinical & Investigative Medicine;Dec99, Vol. 22 Issue 6, p256 

    Objective: Use of vancomycin is a risk factor for acquiring vancomycin-resistant enterococci (VRE). To optimize the use of vancomycin in hospitals, the Hospital Infection Control Practices Advisory Committee (HICPAC) published recommendations in 1995. The objectives of this study were to...

  • Vancomycin.  // Reactions Weekly;3/27/2010, Issue 1294, p36 

    The article describes the case of a 52-year-old woman who acquired creatinaemia, uraemia and urinary infection while undergoing treatment with vancomycin.

  • Vancomycin.  // Reactions Weekly;3/27/2010, Issue 1294, p36 

    The article describes the case of a 64-year-old man who died of sepsis after not responding to vancomycin.

  • Vancomycin.  // Reactions Weekly;7/3/2010, Issue 1308, p33 

    The article describes the case of a man who developed drug rash with eosinophilia and systemic symptoms (DRESS) syndrome while receiving treatment with vancomycin.

  • Ceftobiprole/rifampicin/vancomycin.  // Reactions Weekly;2/12/2011, Issue 1338, p11 

    The article describes the case of a 65-year-old woman who acquired drug rash with eosinophilia and systemic symptoms (DRESS) syndrome while undergoing treatment with vancomycin, and rifampicin and agranulocytosis for taking ceftobiprole.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics